
TRIPCEE-6G Clinical Monograph & Batch COA
Certified DCGI Formulation Literature (PDF)
TRIPCEE-6G
Ketoconazole 2.00%w/w + Clobetasol Propionate 0.05%w/w + Lodochlorhydroxyquinoline 1.00%w/w + Neomycin Sulphate 0.10%w/w + Dexpanthenol 0.05%w/w + Tolnaftate 1.00%w/w
TRIPCEE-6G (Ketoconazole 2.00%w/w + Clobetasol Propionate 0.05%w/w + Lodochlorhydroxyquinoline 1.00%w/w + Neomycin Sulphate 0.10%w/w + Dexpanthenol 0.05%w/w + Tolnaftate 1.00%w/w) is manufactured under strict WHO-GMP compliance for maximum bioavailability and therapeutic efficacy.
Clinical Pharmacology & Therapeutic Profile
Comprehensive therapeutic guidelines for medical practitioners and institutional procurement
Therapeutic Indications
Mechanism of Action (MOA)
The active pharmacological principles in TRIPCEE-6G deliver targeted therapeutic action through standardized systemic bioavailability and verified pharmacodynamics.
As directed by the registered medical practitioner. Strictly adhere to full course duration.
Well tolerated under clinical supervision. Contraindicated in patients with hypersensitivity to active ingredients.
Store in a cool place below 25°C. Do not freeze. Replace cap tightly after use.
WHO-GMP Certified Purity
Manufactured in state-of-the-art HVAC controlled cleanrooms with 100% active ingredient bio-potency and analytical batch testing.
Alu-Alu Moisture Barrier
Superior barrier protection against tropical humidity, preventing physical degradation and guaranteeing 24-month stability.
Exclusive District Monopoly
Strict PCD franchise monopoly allocation ensuring zero price competition and complete territory protection for our partners.
Technical Product Specifications
Active Medical Composition
TRIPCEE-6G features Ketoconazole 2.00%w/w + Clobetasol Propionate 0.05%w/w + Lodochlorhydroxyquinoline 1.00%w/w + Neomycin Sulphate 0.10%w/w + Dexpanthenol 0.05%w/w + Tolnaftate 1.00%w/w prepared to high pharmaceutical purity standards.
*Disclaimer: Formulations are intended solely for distribution to licensed practitioners, hospitals, and pharmacies. Dosage must adhere to medical advice.
Customer & Clinical Reviews
Real feedback from registered physicians, stockists, PCD franchise partners, and verified buyers.
Based on 1 verified review
Evaluated across our institutional for TRIPCEE-5G
TRIPCEE-5G has been evaluated across our institutional healthcare network, leading to verified clinical improvement without secondary complaints or nausea. The pack design is aesthetically modern with distinct therapeutic labeling that eliminates dispensing errors. Both consulting doctors and stocking pharmacists rate this formulation among the best in its class.
Questions Regarding TRIPCEE-6G
What is the therapeutic indication and composition of TRIPCEE-6G?
TRIPCEE-6G contains Ketoconazole 2.00%w/w + Clobetasol Propionate 0.05%w/w + Lodochlorhydroxyquinoline 1.00%w/w + Neomycin Sulphate 0.10%w/w + Dexpanthenol 0.05%w/w + Tolnaftate 1.00%w/w indicated for Indicated for therapeutic management within specified clinical indications under qualified physician guidance. as formulated by Sygnus Biotech.
What packaging presentations are available for TRIPCEE-6G?
TRIPCEE-6G is supplied in tamper-evident 20gm Laminated Aluminum Barrier Tube, engineered with barrier foil protection to ensure a 24 to 36 month shelf life.
Is monopoly PCD franchise territory available for TRIPCEE-6G?
Yes, Sygnus Biotech grants exclusive district-wise monopoly marketing rights for TRIPCEE-6G along with promotional visual aids, product cards, and marketing support.
What is the regulatory schedule and minimum order quantity (MOQ)?
TRIPCEE-6G is categorized as Schedule H with an introductory PCD franchise MOQ of 100 units per batch.





